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intermediate ‑risk patients with favorable anato‑
my.1,2 However, there is an increasing awareness 
of possible transcatheter heart valve thrombo‑
sis (THVT), and this complication seems to be 
a relevant limitation of the current TAVI tech‑
niques. Importantly, a common risk factor for 
IntroductIon Transcatheter aortic valve 
implantation (TAVI) is a well ‑established treat‑
ment method for severe aortic stenosis in el‑
derly patients who are ineligible for surgery 
or at high risk of surgery. Transcatheter aortic 


















Background Conflicting data exist regarding the risk factors for transcatheter heart valve thrombosis 
(THVT). In addition, no optimal pharmacological strategy to treat THVT has been established so far.
aims The aim of this study was to assess the incidence, risk factors, diagnostic workup, and treatment 
of THVT in Poland.
methods Data were collected retrospectively in the multicenter registry of patients with THVT (ZAK ‑POLTAVI) 
between November 2008 and November 2018. Transcatheter heart valve thrombosis was defined as 
an increased mean transvalvular gradient accompanied by a decreased effective orifice area or severe aortic 
regurgitation, reversible after treatment. Baseline characteristics and procedural data were compared 
between patients with THVT and those without THVT (matched by age, sex, and diabetic status).
results In a group of 2307 patients undergoing transcatheter aortic valve implantation (TAVI), 26 patients 
with THVT were identified (incidence, 1.14%). In half of the patients, THVT was diagnosed within 6 months 
after TAVI. As compared with the control group, patients with THVT more frequently had chronic obstructive 
pulmonary disease (P = 0.035), a smaller aortic valve area (P = 0.007), a higher mean postprocedural 
transvalvular gradient (P = 0.037), and a lower platelet count (P = 0.029) at the time of the diagnosis. 
A total of 24 patients (84.6%) received anticoagulation therapy for THVT, and complete resolution of THVT 
was noted in 12 individuals (46.1%). We observed thromboembolic complications in 2 patients (7.7%).
conclusions Transcatheter heart valve thrombosis is a rare complication of TAVI. However, a higher risk 
of THVT may be expected in patients with chronic obstructive pulmonary disease, a smaller aortic valve area, 
a higher mean postprocedural transvalvular gradient, and a lower platelet count. Anticoagulation alone or 
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the decision as to whether treatment with vita‑
min K antagonists (VKAs) / non–vitamin K an‑
tagonist oral anticoagulants (NOACs) with or 
without a single antiplatelet agent should be 
initiated was left at the discretion of the treat‑
ing physician. The platelet count was evaluated 
at the time of diagnosis of THVT. In the control 
group, the last available data were used.
statistical analysis Data were analyzed ac‑
cording to the  established standards of de‑
scriptive statistics. Results were presented as 
the number (percentage) of patients or median 
(interquartile range [IQR]). The control group in‑
cluded 26 patients without THVT, matched by 
age, sex, and diabetic status. Patients were se‑
lected from the database of TAVI procedures per‑
formed in the Institute of Cardiology, Kraków, 
Poland, during the study period. Differences 
between groups were assessed using the χ2 test 
and the Fisher exact test for dichotomous vari‑
ables and the Mann–Whitney test for continu‑
ous variables. All tests were 2‑sided and a P val‑
ue less than 0.05 was considered significant. 
All statistical analyses were performed using 
the Statistica 13.3 software (Tibco Software, Inc., 
Palo Alto, California, United States).
results Between November 2008 and No‑
vember 2018, 2307 TAVI procedures were per‑
formed and 328 Edwards XT and 260 Edwards S3 
(Edwards Lifesciences, Irvine, California, Unit‑
ed States), 489 CoreValve, 826 Evolut R, 107 Evo‑
lut Pro, 3 Engager (Medtronic Scientific, Min‑
neapolis, Minnesota, United States), 119 Lotus 
(Boston Scientific, Marlborough, Massachusetts, 
United States), 17 Jena Valve (JenaValve Tech‑
nology, GmbH, Munich, Germany), 85 Acurate 
Neo (Boston Scientific, Marlborough, Massachu‑
setts, United States), 43 Portico (St. Jude Med‑
ical, Minneapolis, Minnesota, United States), 
and 30 NVT (NVT, GmbH, Hechingen, Germa‑
ny) valves were implanted. During follow‑up, 26 
patients with THVT were identified (the study 
group) based on an increased transvalvular gra‑
dient. Thus, the estimated incidence of THVT 
was low, of about 1.14% (0.3% for Edwards XT, 
2.7% for Edwards S3, 0.8% for CoreValve / Evolut 
R, 5.9% for Lotus, and 2.3% for Portico valves).
The median (IQR) age of patients with THVT 
was 81.5 (76–86) years, and 12 patients were fe‑
male (66.7%) (TABle 1). The increased transvalvu‑
lar gradient was confirmed on echocardiography 
performed at the median (IQR) time of 268 (176–
401) days after TAVI. Thrombosis was observed 
in 13 patients (50%) within 6 months. In 11 pa‑
tients (42.3%), THVT was confirmed later than 
at 12 months after TAVI. Early thrombosis (devel‑
oped earlier than at 3 months) was noted only in 
2 patients (7.7%). We recorded a significant rise of 
the transvalvular gradient with a median (IQR) 
THVT is the absence of anticoagulation.3-7 On 
the other hand, prolonged and aggressive an‑
tiplatelet and / or antithrombotic therapy after 
TAVI may increase the risk of bleeding in elder‑
ly patients with multiple comorbidities. The ma‑
jority of data on THVT come from large stud‑
ies with close follow ‑up, including the analysis 
of advanced imaging and serial multislice com‑
puted tomography (MSCT) scans. Data regard‑
ing the detection of THVT in everyday practice 
are limited. Thus, we sought to assess the inci‑
dence, diagnostic workup, treatment, and out‑
comes of THVT in daily clinical practice.
Methods In the Polish Registry of Valve 
Thrombosis after Transcatheter Aortic Valve 
Implantation (Polish, Polski Rejestr Zakrzepicy 
Przezskórnie Wszczepianej Zastawki Aortal‑
nej [ZAK ‑POLTAVI]), 6 centers were asked to 
fill in a questionnaire regarding periprocedur‑
al and follow ‑up data of TAVI procedures con‑
ducted between November 2008 and Novem‑
ber 2018. Data were collected retrospectively. 
Transcatheter heart valve thrombosis was de‑
fined as an increased mean transvalvular gradi‑
ent accompanied by a decreased effective orifice 
area (EOA), reversible after treatment. Alterna‑
tively, it was regarded as an inexplicable, early 
rise of the mean gradient (eg, with no signs of 
endocarditis or improvement of left ventricu‑
lar stroke volume) or new, reversible after treat‑
ment, severe aortic regurgitation.8 Transthoracic 
echocardiography (TTE) was used as a standard, 
first ‑line diagnostic tool and, in the majority of 
centers, TTE findings were verified using trans‑
esophageal echocardiography (TEE) or MSCT. 
Standard post ‑TAVI treatment differed among 
the 6 centers, but included single antiplatelet 
therapy with aspirin (75 mg/d) or dual antiplate‑
let therapy (DAPT) with aspirin (75 mg/d) and 
clopidogrel (75 mg/d) for 6 months, followed by 
lifelong aspirin therapy (75 mg/d). In patients 
with indications for oral anticoagulants (OACs), 
whAt’s new?
There is an increasing awareness of possible transcatheter heart valve 
thrombosis (THVT). However, data regarding the detection of this condition 
in everyday practice are limited. In this article, we reported data on THVT in 
Poland. The incidence of THVT in the study patients treated with transcatheter 
aortic valve implantation was 1.14%. The risk factors for THVT included chronic 
obstructive pulmonary disease, a smaller aortic valve area, a higher mean 
postprocedural transvalvular gradient, and a lower platelet count. The majority 
of patients received anticoagulation as the first ‑line treatment for THVT, and 
complete resolution of THVT was observed in half of the patients. In 2 patients, 
thromboembolic complications of THVT were confirmed. Nonetheless, in some 
patients, discontinuation of anticoagulation may be the reason for THVT 
recurrence. Further studies are needed to define the optimal pharmacological 
treatment to prevent and treat THVT.
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Table 1 Baseline characteristics along with echocardiographic and procedural data of the study patients
Variable Patients with valve thrombosis (n = 26) Matched controls (n = 26) P value
Age, y 82 (77–86) 81.5 (75–84) 0.61
Female sex 18 (69.2) 18 (69.2) 0.99
BMI, kg/m2 25.5 (23.9–30.6) 28.3 (26.6–32.4) 0.14
eGFR, ml/min/1.73 m2 60 (50–70) 47 (37–67) 0.08
Platelets, × 103/µl 163 (151–209) 211.5 (173–235) 0.029
Platelets <150 × 103/µl 6 (23.1) 2 (7.7) 0.25
NYHA class III or IV 16 (61.5) 20 (76.9) 0.23
Arterial hypertension 23 (88.5) 25 (96.2) 0.61
Diabetes 9 (34.6) 9 (34.6) 0.99
Atrial fibrillation 8 (30.8) 9 (34.6) 0.77
Previous MI 8 (30.8) 10 (38.5) 0.56
Previous PCI 12 (46.2) 8 (30.8) 0.25
Previous CABG 3 (11.5) 4 (15.4) 0.99
COPD 8 (30.8) 2 (7.7) 0.035
Previous stroke / TIA 3 (11.5) 1 (3.8) 0.61
Pacemaker 0 1 (3.8) 0.67
Logistic EuroSCORE I, % 11.4 (8.9–16.5) 18.6 (9–24.8) 0.11
STS score, % 4.1 (3.4–6.9) 4.8 (3.6–8.1) 0.53
Baseline AV transvalvular gradient, mm Hg, mean (range) 56.5 (37–74) 50 (40–60) 0.49
Baseline AV area, cm2 0.5 (0.4–0.8) 0.7 (0.6–0.9) 0.007
Baseline LVEF, % 52.5 (40–60) 60 (40–65) 0.32
Baseline SPAP, mm Hg 47 (34–50) 48 (41–68) 0.15
Baseline aortic regurgitation grade 3 or 4 4 (19.2) 0 0.05
Transfemoral access 25 (96.2) 21 (80.8) 0.05
Device implanted CoreValve and / or Evolut R 10 (38.5) 8 (30.8) 0.19
Edwards Sapien 8 (30.8) 14 (53.8)
Lotus 7 (26.9) 2 (11.5)
Jena 0 1 (3.8)
Portico 1 (3.8) 0
Prosthesis size 23 mm 10 (38.5) 7 (26.9) 0.74
25 mm 1 (3.8) 1 (3.8)
26 mm 7 (26.9) 9 (34.6)
27 mm 2 (7.7) 0
29 mm 5 (19.2) 8 (30.8)
31 mm 1 (3.8) 1 (3.8)
Maximal postprocedural AV transvalvular gradient, mm Hg 24 (20–30) 16.5 (12–24) 0.005
Postprocedural AV transvalvular gradient, mm Hg, mean (range) 14 (9.5–18) 9.5 (6–13) 0.012
Postprocedural LVEF, % 50 (45–55) 50 (35–60) 0.83
Postprocedural aortic regurgitation grade 3 or 4 0 0 0.99
Data are presented as the number (percentage) of patients or median (interquartile range) unless otherwise indicated.
Abbreviations: AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SPAP, systolic 
pulmonary artery pressure; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack
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carries an increased risk of embolic events and 
may impact valve durability. On the other hand, 
THVT is not always symptomatic. Thus, its detec‑
tion may require more attention during follow‑
‑up. The observed incidence of 1.14% was low yet 
comparable to that reported in a study by Latib 
et al9 who reported the incidence of 0.6% when 
only TTE was used for detection of THVT. Im‑
portantly, conventional post ‑TAVI TTE follow‑
‑up is the most frequent method for valve as‑
sessment, which is inferior to contrast ‑enhanced 
MSCT for the detection of THVT. Using MSCT, 
2 various types of THVT can be determined: hy‑
poattenuated leaflet thickening and hypoatten‑
uation affecting motion.10 Thus, diagnosis based 
on MSCT increased the sensitivity for THVT 
detection to up to 6.1% to 14.3%. Transthoracic 
echocardiography enables clinicians to diagnose 
the rise of the transvalvular gradient due to re‑
duced leaflet motion (the stage of hypoattenu‑
ation affecting motion). Hypoattenuated leaf‑
let thickening is difficult or even impossible to 
visualize using TTE and it is also referred to as 
subclinical valve thrombosis. However, the as‑
sessment of the thickness of the transcatheter 
heart valve leaflet and its mobility by TEE is most 
likely improved compared with MSCT, owing 
to the superior temporal resolution of TEE.10,11
In addition, as heterogenous criteria for 
the diagnosis of THVT exist, the described 
frequency may also be affected by the defini‑
tion adopted.8-13 For example, the Valve Aca‑
demic Research Consortium‑2 defines struc‑
tural valve deterioration as valve ‑related dys‑
function (mean aortic gradient >20 mm Hg, 
EOA <0.9–1.1 cm2, and / or dimensionless valve 
index <0.35, and / or moderate or severe pros‑
thetic valve regurgitation) or need for a repeat 
procedure (TAVI or surgical aortic valve replace‑
ment).12 Lancellotti et al14 suggested incorpo‑
rating an increase in the mean gradient during 
stress echocardiography at follow ‑up to the cri‑
teria of possible obstruction (mean transvalvular 
gradient, 10–19 mm Hg) and significant obstruc‑
tion (mean transvalvular gradient >20 mm Hg). 
In our study, we used the definition proposed 
by Pislaru et al,8 with an additional criterion of 
the increase in the transvalvular gradient larg‑
er than 50% of the baseline value (in the ab‑
sence of increased stroke volume), particularly 
useful in the low ‑flow, low ‑gradient conditions. 
Of note, in selected cases, the rise of the trans‑
valvular gradient can be a result of left ventric‑
ular ejection fraction improvement after TAVI.
Importantly, risk factors for THVT have not 
been defined yet. For instance, conflicting data 
regarding the impact of sex and valve size on 
the risk of THVT exist.7,9,13,14 In our small group 
of patients with THVT, most subjects were fe‑
male and had small valves. In addition, a high‑
er transvalvular postprocedural gradient and 
smaller preprocedural AVA were observed in 
maximal transvalvular gradient of 44.5 (32–
72) mm Hg and a mean (minimum–maximum) 
gradient of 23 (19–41) mm Hg. Additionally, a de‑
crease in the median (IQR) EOA from 1 (1–2) cm2 
after the procedure to 1 (1–1) cm2 at follow ‑up was 
observed. The majority of patients demonstrat‑
ed dyspnea exacerbation (13 patients [72.2%]). In 
our study group, TEE was performed in 8 patients 
(30.8%), MSCT in a single patient (3.8%), both 
modalities were used in 11 patients (42.3%), and 
none of them in 6 patients (23.1%). At the time of 
THVT diagnosis, patients were still on DAPT (12 
patients [46.2%]) or aspirin (7 patients [26.9%]). 
Seven patients (26.9%) were treated with OACs, 
including 3 individuals (11.5%) receiving the com‑
bination of a NOAC and a single antiplatelet agent.
As compared with the control group, patients 
with THVT more frequently had chronic obstruc‑
tive pulmonary disease (P = 0.035), a smaller 
aortic valve area (AVA) (P = 0.007), and a higher 
mean postprocedural transvalvular gradient (P 
= 0.037). There was no difference between groups 
in the percentage of patients with a platelet count 
below 150 × 103/μl (TABle 1). The platelet count was 
lower in the THVT group (median [IQR], 163 
[151–209] vs 211.5 [173–235]; P = 0.029).
A large variability in subsequent treatment 
was observed. For the treatment of THVT, 24 
patients (84.6%) received anticoagulation, in‑
cluding 8 patients (30.8%) on anticoagulation 
alone, 6 (23.1%) on anticoagulation and aspirin, 
8 (30.8%) on anticoagulation and clopidogrel, 
and 2 (7.7%) on anticoagulation and DAPT. In 
2 patients (7.7%), current treatment with aspi‑
rin alone (1 case) and DAPT (1 case) was main‑
tained. Importantly, in 3 patients (11.5%) al‑
ready receiving VKAs, the target international 
normalized ratio was raised from 2.5 to 3. Com‑
plete resolution of THVT was observed in 12 pa‑
tients (46.1%). Only a slight improvement was 
confirmed in 8 patients (30.8%), and no change 
of the gradient was seen in 6 patients (23.1%; 
including 4 treatment ‑naive patients). Embolic 
events were noted in 2 patients (7.7%)—central 
retinal artery embolization and ischemic stroke 
in each case separately—interestingly, just af‑
ter starting anticoagulation. In a single patient, 
THVT recurred after transient discontinuation 
of warfarin, despite the use of enoxaparin as 
a bridge to noncardiac surgery. A patient with 
atrial fibrillation underwent left atrial append‑
age closure with the Watchman device and re‑
quired blood transfusion because of gastroin‑
testinal bleeding. In that patient, a significant 
increase of the transvalvular gradient was ob‑
served following anticoagulation withdrawal.
dIscussIon Transcatheter heart valve 
thrombosis is a rare yet potentially dangerous 
complication that may affect various types of 
valves used for TAVI. Importantly, this condition 
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antithrombotic treatment initiated to manage 
this complication and / or differences in the tim‑
ing of platelet count assessment between groups. 
A temporal drop of the platelet count is a known 
phenomenon following bioprosthesis implan‑
tation, associated with unfavorable outcomes 
after TAVI.19
Other risk factors for THVT include nonuse of 
post ‑TAVI VKA treatment or allergy to any stent 
material. The majority of the study patients were 
observed in the last 2 years when newly devel‑
oped valve types were used. New technologies 
reduce the risk of paravalvular leaks using addi‑
tional materials (eg, skirt) to seal the space be‑
tween the valve stent and calcifications of the 
leaflets and the annulus. However, such mate‑
rials, long scaffolds in particular, might incite 
thrombus formation. Other theories have sug‑
gested that the prothrombotic effect of a metal 
stent and the importance of neosinus formation 
with turbulent flow.20 Transcatheter heart valve 
thrombosis is more frequent in patients treated 
with balloon ‑expandable valves.7 Interestingly, 
in our study group, THVT was also more com‑
mon in patients with chronic obstructive pulmo‑
nary disease and those with a lower glomerular 
filtration rate. Thus, the general inflammatory 
status may play a crucial role in the development 
the THVT group. Therefore, potentially, a more 
calcified valve with a smaller AVA and possible 
underexpansion of the implanted valve (with 
a higher postprocedural gradient) might be 
a risk factor for THVT. On the contrary, a larg‑
er size of the implanted valve was suggested to 
be associated with the slow flow (especially in 
the base of the sinus of Valsalva) and a higher 
risk of THVT.7 In addition, the valve ‑in ‑valve 
procedure was also found to be a risk factor for 
THVT.7,15 Interestingly, the higher transvalvu‑
lar gradient may correspond with elevated shear 
stress. This may cause platelet activation and 
enhance the prothrombotic state.16 On the oth‑
er hand, shear stress may play a role in bleeding 
complications by shedding of the platelet recep‑
tor and loss of high ‑molecular ‑weight multim‑
ers of von Willebrand factor.16,17 Other authors 
suggested that there may be an interaction be‑
tween high shear stress and platelet activation 
by a potential platelet disruption effect due to 
a high transvalvular gradient.17,18 The observed 
platelet count was lower in the THVT group 
compared with the control group, and no dif‑
ference was observed in the rate of thrombo‑
cytopenia. Although a cause–effect relation‑
ship cannot be ruled out, the lower platelet 
count in the THVT group might be related to 
Figure 1 Illustrative case 1. At routine follow -up 6 months after Evolut R Pro valve implantation, an 83-year -old man reported 
no symptoms, but a slight increase of the transvalvular gradient on transthoracic echocardiography and reduced leaflet motion on 
transesophageal echocardiography (TEE) were observed. The patient showed good response to vitamin K antagonist and 
clopidogrel treatment, but recurrence was noted after discontinuation of vitamin K antagonist therapy. a – long -axis TEE view of 
the valve placed during the transcatheter aortic valve implantation (TAVI) procedure: 2-dimensional (left) and color Doppler (right) 
imaging at the same projection showing limited leaflet motion (red arrow) with reduced flow (yellow arrows) and the thrombus 
(green arrow); B – 3‑dimensional TEE reconstruction of the TAVI valve demonstrating reduced mobility of the leaflet (red arrows); 
c – long -axis TEE view of the TAVI valve: 2-dimensional (left) and color Doppler imaging (right) at the same projection showing 
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but with satisfactory clinical outcomes. Oth‑
er authors also reported spontaneous resolu‑
tion of THVT.6 This phenomenon may explain 
the discrepancy between the incidence of inci‑
dental THVT and clinically overt, obstructive 
THVT. A single patient required surgery and 
postoperative complications resulted in death. 
Most importantly, THVT carries an increased 
risk of embolic events and may affect valve du‑
rability.20,11 In our study group, a single case of 
central retinal artery embolization and another 
case of ischemic stroke were observed.
limitations Our study was limited by retro‑
spective data collection and unavailability of 
MSCT scans to confirm the diagnosis in the ma‑
jority of patients. Identification of THVT predic‑
tors was not possible due to incomplete clinical 
data for all patients without this complication, 
treated during the study period. To address this 
limitation, we compared baseline characteris‑
tics and procedural data of patients with THVT 
with matched controls without THVT. However, 
the data of matched controls were retrieved only 
from a single center. The majority of THVT cas‑
es were identified in the final part of the enroll‑
ment period. It may indicate an increased aware‑
ness and the learning curve for detection of THVT 
using TEE and MSCT.
of THVT in patients after TAVI. Interestingly, 
a higher body mass index was suggested to have 
a protective effect in patients undergoing TAVI,21 
being numerically higher in patients without 
THVT. We cannot exclude the impact of the body 
mass index, as well as other body composition 
parameters, on the risk of THVT. Further larger 
studies are needed to address this issue.
According to recent guidelines, surgical, non‑
critical valve thrombosis should be treated with 
VKA and aspirin.2 In line with the previous stud‑
ies, anticoagulation combined with VKA was ef‑
fective in most of our study patients and an in‑
crease of the mean EOA after treatment was 
confirmed (FIGUre 1). We did not observe any sig‑
nificant drop in the transvalvular gradient, pos‑
sibly because of lack of VKA treatment in 2 pa‑
tients and the delayed treatment start in a sin‑
gle patient (FIGUre 2). The observed recurrence of 
THVT after discontinuation of warfarin may in‑
dicate that short ‑term warfarin treatment may 
be insufficient.13 Also, a limited treatment effect 
was observed in a patient with delayed treat‑
ment initiation, which may indicate the sig‑
nificance of early THVT detection and initia‑
tion of anticoagulation to prevent deteriora‑
tion of the valve function. We observed 2 pa‑
tients with obstructive THVT without amelio‑






Figure 2 Illustrative case 2. At follow -up at 6 months after Lotus 23 valve implantation, a 82-year -old woman presented with symptoms typical of New York Heart 
Association class III / IV, gradually worsening starting from 2 months after the procedure. Treatment with a reduced dose of enoxaparin was delayed because of 
transient ophthalmologic contraindications. Complete symptom resolution was not achieved, but relief and a reduced gradient during treatment were observed. 
a–c – Lotus valve thrombosis: a – 2-dimensional (left) and color Doppler (right) long -axis transesophageal echocardiography (TEE) view of the transcatheter aortic 
valve, showing a decreased leaflet opening (red arrow) and a thrombus (green arrows); B – right parasternal TTE view: a continuous-wave (CW) aortic transvalvular 
gradient of 81/53 mm Hg; c – computed tomography angiography showing a thrombus (green arrows) on the Lotus valve and reduced leaflet motion (red arrows). 
d–F – TEE after pharmacological treatment: d – long ‑axis parasternal color Doppler TTE view demonstrating larger flow through the valve (yellow arrows); e – right 
parasternal TTE view showing a reduced CW transvalvular gradient of up to 42/27 mm Hg; F – computed tomography angiography demonstrating a considerable 
improvement of thrombosis
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conclusions In conclusion, THVT is a rare 
complication of TAVI and may be observed after 
implantation of various types of valves. A higher 
risk of THVT may be expected in patients with 
chronic obstructive pulmonary disease, a smaller 
AVA, a higher mean postprocedural transvalvu‑
lar gradient, and a lower platelet count. The opti‑
mal antiplatelet and antithrombotic therapy to 
prevent and treat this complication still needs 
to be investigated, although OACs with or with‑
out antiplatelet therapy seem to be effective.
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